{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:10:30Z","timestamp":1774437030854,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:00:00Z","timestamp":1369872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40262-013-0083-4","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T12:52:12Z","timestamp":1369831932000},"page":"995-1004","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1\u201331)NH2] in Postmenopausal Women with Osteoporosis"],"prefix":"10.1007","volume":"52","author":[{"given":"Amy","family":"Sturmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozer","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Giacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulin","family":"Cagatay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanne","family":"Tavakkol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Mitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Trang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,30]]},"reference":[{"key":"83_CR1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD. Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250\u201361.","journal-title":"N Engl J Med"},{"key":"83_CR2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018\u201326.","journal-title":"Lancet"},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1517\/14712598.2010.506870","volume":"10","author":"HJ Verhaar","year":"2010","unstructured":"Verhaar HJ, Lems WF. PTH analogs and osteoporotic fractures. Expert Opin Biol Ther. 2010;10:1387\u201394.","journal-title":"Expert Opin Biol Ther"},{"key":"83_CR4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0091270010372625","volume":"51","author":"MA Karsdal","year":"2011","unstructured":"Karsdal MA, Henriksen K, Bay-Jensen AC, et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol. 2011;51:460\u201371.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"83_CR5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","volume":"87","author":"J Satterwhite","year":"2010","unstructured":"Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1\u201334]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485\u201392.","journal-title":"Calcif Tissue Int"},{"key":"83_CR6","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1210\/jc.84.8.2739","volume":"84","author":"LJ Fraher","year":"1999","unstructured":"Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone-(1\u201331)NH2 and hPTH(1\u201334) in healthy humans. J Clin Endocrinol Metab. 1999;84:2739\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"83_CR7","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1021\/bi00027a035","volume":"34","author":"W Neugebauer","year":"1995","unstructured":"Neugebauer W, Barbier J-R, Sung J, et al. Solution structure and adenylyl cyclase stimulation activities of C-terminal truncated human parathyroid hormone analogues. Biochemistry. 1995;34:8835\u201342.","journal-title":"Biochemistry"},{"issue":"Suppl 1","key":"83_CR8","first-page":"1249","volume":"24","author":"N Mehta","year":"2009","unstructured":"Mehta N, Erickson K, Stern W, et al. Pharmacokinetic clinical studies of an orally delivered recombinant PTH analog. J Bone Miner Res. 2009;24(Suppl 1):1249.","journal-title":"J Bone Miner Res"},{"key":"83_CR9","unstructured":"Whitfield J, Morley P, Langille R, et al. Adenyl cyclase-activating anabolic agents. In: Whitfield JF, Morley P, editors. Parathyroid hormone and prostaglandins E in anabolic treatments for osteoporosis. CRC Press LLC; 1998."},{"key":"83_CR10","unstructured":"Eli Lilly and Company. Forteo Product Information; 2010."},{"key":"83_CR11","unstructured":"Perron 2001. Teriparatide injection (rDNA origin). US Food and Drug Administration Documents Management. Updated February 1, 2010. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/slides\/3761s2_01_lilly\/sld078.htm ."},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2012.11.045","volume":"53","author":"K Henriksen","year":"2013","unstructured":"Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the safety and efficacy of oral human parathyroid hormone [rhPTH(1\u201331)NH2] compared to teriparatide in postmenopausal women with osteoporosis. Bone. 2013;53:160\u20136.","journal-title":"Bone"},{"key":"83_CR13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11095-010-0192-9","volume":"28","author":"PE Daddona","year":"2010","unstructured":"Daddona PE, Matriano JA, Mandema J, et al. Parathyroid hormone (1\u201334)-coated microneedle patch sytem: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res. 2010;28:159\u201365.","journal-title":"Pharm Res"},{"issue":"4","key":"83_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s001980050151","volume":"9","author":"T Fujita","year":"1999","unstructured":"Fujita T, Inoue T, Morii H. Effect of an intermittent weekly dose of human parathyroid hormone (1\u201334) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int. 1999;9(4):296\u2013306.","journal-title":"Osteoporos Int"},{"issue":"2","key":"83_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1210\/jc.2011-2332","volume":"97","author":"R Baron","year":"2012","unstructured":"Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. JCEM. 2012;97(2):311\u201325.","journal-title":"JCEM"},{"issue":"8","key":"83_CR16","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","volume":"96","author":"LA Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LA, Dabrowski DE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2011;96(8):2441\u20139.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0083-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0083-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T08:03:13Z","timestamp":1595836993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0083-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,30]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0083-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,30]]}}}